Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend (12mg) – Triple-Action Metabolic Research Peptide

Welcome to Liaocheng Yixin Company, your trusted source for premium fragment 176-191 mod grf 1-29 ipamorelin blend 12mg for research. As a specialized peptide synthesis manufacturer operating from our facility at No. 9 Lushan Road, Dongcheng Street, Liaocheng Economic and Technological Development Zone, Shandong Province, we provide high-quality research compounds for the global scientific community.

This 12mg triple-action blend combines three synergistic peptides to support metabolic and endocrine research applications. Fragment 176-191, Mod GRF 1-29, and Ipamorelin each target distinct but complementary pathways within the growth hormone axis . Our fragment 176-191 mod grf 1-29 ipamorelin blend 12mg for research offers investigators a convenient, precisely formulated tool for studying fat metabolism, growth hormone signaling, and cellular regeneration .

What is the Fragment 176-191, Mod GRF 1-29 & Ipamorelin Blend?

This 12mg lyophilized blend contains three research peptides that work through complementary mechanisms :

Fragment 176-191 is a synthetic peptide corresponding to the C-terminal region of human growth hormone, hypothesized to target adipose tissues for lipolytic research . Mod GRF 1-29 is a tetrasubstituted GHRH analog with enhanced stability, often referred to as CJC-1295 without DAC . Ipamorelin is a selective growth hormone secretagogue known for its ability to stimulate GH release without substantially impacting cortisol or prolactin levels .fragment 176-191 mod grf 1-29 ipamorelin blend 12mg for research

Mechanism of Action in Research

Each component of the blend targets a distinct but interconnected pathway :

Fragment 176-191 – Direct Lipolytic Activity

Fragment 176-191 is hypothesized to act directly on adipose cells through several mechanisms. Research suggests it stimulates hormone-sensitive lipase (HSL), breaking stored triglycerides into free fatty acids and glycerol . Studies indicate that Fragment 176-191 may increase adipocyte sensitivity to lipolytic signals by influencing β3-adrenergic receptor (β3-AR) expression . Importantly, it does not significantly activate the GH receptor or increase IGF-1 levels, making it valuable for studying fat metabolism independently of systemic growth hormone effects .

Mod GRF 1-29 – GHRH Receptor Signaling

Mod GRF 1-29 binds to GHRH receptors on somatotrophs in the anterior pituitary gland. Upon binding, it activates the adenylyl cyclase pathway, converting ATP to cAMP, activating protein kinase A (PKA), and ultimately facilitating calcium influx and growth hormone release . Modified GRF 1-29 has been shown to support a 70% to 107% increase in the 12-hour area under the curve of hGH concentrations .fragment 176-191 mod grf 1-29 ipamorelin blend 12mg for research

Ipamorelin – Selective Ghrelin Receptor Agonism

Ipamorelin is a ghrelin-mimetic that interacts with the growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus . Its reputed selectivity allows it to preferentially engage somatotropic signaling pathways while exhibiting minimal interaction with cortisol or prolactin-associated systems .

Synergistic Amplification

The combination of Mod GRF 1-29 (GHRH pathway) and Ipamorelin (GHS-R pathway) may produce synergistic GH release exceeding the sum of individual peptide effects . This mirrors the physiological interplay between endogenous GHRH and ghrelin, where concurrent stimulation amplifies GH pulse amplitude significantly compared to either signal alone .

Scientific Research Applications

Metabolic and Fat Metabolism Research

Fragment 176-191 has been studied in obese murine models, where it appeared to support significant reduction in body weight and excess body lipids . Research suggests the peptide may support fat breakdown via energy expenditure and fat oxidation, potentially through the beta-adrenergic pathway . A 2004 clinical trial involving 300 obese subjects examined Fragment 176-191 over 12 weeks, with one test group appearing to exhibit up to an average of 2.8 kilograms weight reduction and improved cholesterol profiles .

Endocrine Signaling Studies

This blend is used to study the interconnected pathways of GH regulation. The vertical integration of Mod GRF 1-29 and Ipamorelin with Fragment 176-191 allows researchers to examine both upstream GH modulation and downstream metabolic effects simultaneously .fragment 176-191 mod grf 1-29 ipamorelin blend 12mg for research

Pharmacokinetic and Pharmacodynamic Research

The differing half-lives and receptor selectivities of the three components support comparative research into combined GH secretagogue therapies and pharmacokinetic modeling .

Why Choose Liaocheng Yixin Company?

When sourcing fragment 176-191 mod grf 1-29 ipamorelin blend 12mg for research, quality and reliability are paramount. Here’s why researchers trust us:

Manufacturer-Direct Quality

We are a legitimate, licensed peptide synthesis company with a physical headquarters in Shandong Province, China. Our facility maintains strict quality control standards.

Verified Purity Standards

Every batch undergoes rigorous testing using HPLC analysis. Certificates of Analysis confirming purity exceeding 99% are available upon request .

Research-Grade Specifications

• Components: Fragment 176-191, Mod GRF 1-29, Ipamorelin

• Total Mass: 12mg lyophilized powder

• Purity: ≥99% verified by HPLC

• Appearance: White lyophilized powder

• Storage: Store powder at -20°C in a sealed container, protected from light and moisture

• Form: Lyophilized powder for research use

• fragment 176-191 mod grf 1-29 ipamorelin blend 12mg for research

Quality Assurance & Testing

Every batch undergoes comprehensive quality control:

1. Synthesis by experienced chemists using solid-phase peptide synthesis

2. Purification via preparative HPLC

3. Analysis using HPLC for purity verification

4. Mass Spectrometry for molecular weight confirmation

5. Packaged in sterile conditions for research use

6. fragment 176-191 mod grf 1-29 ipamorelin blend 12mg for research

: What research applications use this triple blend?

A: The blend is used in metabolic research (adipose tissue metabolism, lipolysis studies), endocrine dynamics studies (GH secretion pathways), and pharmacokinetic/pharmacodynamic research .

: How does this blend differ from other peptide stacks?

A: This triple blend combines a direct lipolytic fragment (Fragment 176-191) with two complementary GH secretagogues (Mod GRF 1-29 and Ipamorelin). This vertical integration allows researchers to study both upstream GH modulation and downstream metabolic effects simultaneously .

: What is the rationale for combining these three peptides?

A: The rationale is based on complementarity rather than redundancy. Fragment 176-191 acts directly on adipose cells, while Mod GRF 1-29 and Ipamorelin work synergistically to support GH release through two distinct receptor pathways .

: What purity level can I expect?

A: All batches are tested to ensure ≥99% purity by HPLC analysis. Certificates of Analysis are available upon request.

: Is this product for human use?

A: No. This triple blend is manufactured strictly for research use only (RUO). It is not intended for human consumption or clinical applications .

When you need premium fragment 176-191 mod grf 1-29 ipamorelin blend 12mg for research for your metabolic, endocrine, or pharmacokinetic studies, choose a manufacturer that prioritizes quality, transparency, and reliability. Liaocheng Yixin Company combines expert peptide synthesis capabilities with rigorous quality control to deliver research materials you can trust.